BIO-Europe Spring(R) 2008 To Feature Biotech's Biggest Names To Explore The Hottest Issues In The Industry
Key program highlights of BIO-Europe Spring 2008 include:
- There must be a better way - how to increase productivity with new clinical development strategies. Moderated by Barbara Kosacz, Partner and Head of Life Sciences Practice, Cooley Godward Kronish LLP, this plenary session delves into effects of the rapid changes within the global drug development industry. While big pharma is trying to reinvent itself with R&D and in-licensing operations that are more nimble, decisive and entrepreneurial in character, private equity, specialty pharma, and mid-tier pharma are also looking to acquire and develop the most promising phase II assets. This discussion will help answer who will emerge as the dominant force in this competition for assets. How will biotech companies position themselves to work with a growing variety of potential partners or acquirers, and will they be suppliers to- or competitors of Big Pharma in the future?
- Out-Licensing - Why Big-Pharma is so reluctant to partner out and why they shouldn't be. Not many Big Pharma players are very proactive in out-licensing, however some of them seem to revive out-bound partnering activities recently and there are more and more examples of successful deals and out-licensed compounds reaching the market. Shelved compounds from Big Pharma can still be of high interest to small companies and Specialty Pharma. Investors would like to fund more out-licensing deals, but the originators often want to keep their stake in the asset. This workshop features panellists Dr. Ellen Strahlman, Vice President, Licensing, Worldwide Business Development, Pfizer, Inc. and Juergen Heitmann, Head of Out-licensing, Novartis Pharma, and will provide insights into creative deal structuring to allow both partners to identify sufficient value in a deal and to avoid regrets later on.
- Deal Timing: Understanding the Indicators of When to Do a Deal and Choosing the Optimal Point in Time for Your Compound. Why does a deal occur at a given point in a compound's development plan? The answer is different for each compound. For licensing executives, the question of when to complete a deal can be a difficult one. Executives typically look for a product's "sweet spot" - the point in time at which risk and financial reward are equally balanced. This interactive panel moderated by Ben Bonifant, VP, Business Development Practice, Campbell Alliance, and featuring Dr. Vincent Mutel, CEO, Addex Pharmaceuticals and Michael A. Margolis, Vice President, Investment Banking, Rodman & Renshaw, LLC will review timing trends over the past year and analyze the indicators for when a deal might or should occur. Learn from personal experiences shared by those who have made-or helped make-the decision of when to do a deal.
- The Secret Life of CEOs. Mike Ward, Senior Editor, BioCentury Publications Inc. will lead a panel of successful CEOs, including Bernard Gilly, FOVEA Pharmaceuticals SA; Dr. Bart Wuurman, AM-Pharma BV; Dr. Christian Rohlff, Oxford Genome Sciences Ltd; and, Dr. Rainer Wessel, Ganymed Pharmaceuticals AG, who will give an insight into what it really means to be in charge of a biotech company today. What are the most important skills for a CEO to have and where can he/she learn them? And what experiences from their lives outside biotech have helped them run their companies?
Issues that they will consider will include what was the biggest surprise that they had when they were promoted and what is still surprising them today? What are the challenges that CEOs face every day and what are the issues that keep them up at night?
Other workshops and panels include:
- The Pharma Excitement Over RNAi and Antisense Technology
- Beyond Targeted Therapeutics - How will Pharma Value the next Generation of Oncology Companies
- Alzheimer's Partnerships - the Valuation Dilemma
- Regenerative Medicine: Evaluating the Hype, the Hope and the Reality
- Creating Value in the Young Life Science Company
- Europe: Turning Ambition into Business
- Why should BD care about Translational Medicine?
- Global Partnering - Building (or Stumbling) Blocks of International Licensing
- Clusters' Cooperation: Benefits for Companies
- Developing a Globalization Strategy - what small Biotech can learn from Big Pharma
- Bio-similars: Risk taking vs. Caution?
- Funding Early Stage Deals in Europe
Entry to BIO-Europe Spring® 2008 is free to the media, including full access to the partnering system, sessions, press conferences, workshops, and pre-arranged partnering meetings. Visit the BIO-Europe Spring conference website at http://www.ebdgroup.com/bes/press_reg.htm for detailed information on this year's conference and online registration. When you register online, please indicate in the comment field that you are requesting a complimentary press registration. Please fax a copy of your press pass to complete your complimentary media registration to fax number +49 (89) 23 88 756 55.
About BIO-Europe Spring 2008
The BIO-Europe Spring® event brings together international decision-makers from all sectors of the biotechnology industry, and features the successful combination of one-to-one meetings, company presentations, panel discussions and a lively exhibition.
Positioned as the springtime counterpart to EBD Group's flagship conference, BIO-Europe, the BIO-Europe Spring event continues the tradition of providing life science companies with high caliber partnering opportunities. The event enables biotechnology companies to identify, meet and network with companies across the life sciences value-chain from large biotech and pharma companies to financiers and innovative start-ups.
About EBD Group
EBD Group is the leading partnering firm for the global biotechnology industry. Since 1993, firms in the life sciences have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships that drive their business. EBD Group's conferences (run in collaboration with leading industry partners and international trade associations) include BIO-Europe, the world's largest stand-alone life science partnering conference (co-organized with BIO); BIO-Europe Spring®; and BioEquity Europe (co-organized with BioCentury Publications and BIO). EBD's novel, web-based, partnering service partneringONE™ is also used at numerous third-party events around the world. Outside of the conference format, EBD Group's consultants can provide hands-on assistance for firms seeking to in- or out-license products and technologies. EBD Group has offices in USA and Europe.
EBD Group
Bio-Europa de primãvarã (R) 2008 biotehnologii pentru a facilitate mai mari nume de cea mai tare pentru a explora probleme, în industria - BIO-Europe Spring(R) 2008 To Feature Biotech's Biggest Names To Explore The Hottest Issues In The Industry - articole medicale engleza - startsanatate